Reflecting on the advancements of HFrEF therapies over the last two decades and predicting what is yet to come

What was once considered a topic best avoided, managing heart failure with reduced ejection fraction (HFrEF) has become the focus of many drug and device therapies. While the four pillars of guideline-directed medical therapies have successfully reduced heart failure hospitalizations, and some have...

Descripción completa

Detalles Bibliográficos
Autores principales: Piña, Ileana L, Gibson, Gregory T, Zieroth, Shelley, Kataria, Rachna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
#GDMTWorks: The Race to Initiating and Optimizing HFrEF Therapies Supplement Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762889/
https://www.ncbi.nlm.nih.gov/pubmed/36545229
http://dx.doi.org/10.1093/eurheartjsupp/suac112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762889/
https://www.ncbi.nlm.nih.gov/pubmed/36545229
http://dx.doi.org/10.1093/eurheartjsupp/suac112

Ejemplares similares